We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
-4.04%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$317M
AUM Growth
-$74.8M
(-19%)
Cap. Flow
-$34M
Cap. Flow
% of AUM
-10.74%
Top 10 Holdings %
Top 10 Hldgs %
58.38%
Holding
40
New
11
Increased
7
Reduced
13
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$26.2M |
| 2 |
Cigna
CI
|
+$17.8M |
| 3 |
Merck
MRK
|
+$16M |
| 4 |
Pfizer
PFE
|
+$15.8M |
| 5 |
Amgen
AMGN
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$20.3M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$18M |
| 3 |
Abbott
ABT
|
+$17.5M |
| 4 |
AET
Aetna Inc
AET
|
+$17.3M |
| 5 |
CVS Health
CVS
|
+$14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.36% |
| 2 | Financials | 2.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AstraZeneca
AZN
$255B
| $26.5M | 8.36% |
+378,855
| New | +$26.2M |
|
|
EXAS
2
PUT
DELISTED
Exact Sciences
EXAS
| $21.9M | 6.9% |
541,900
+536,359
| +9,680% | +$26.2M |
|
|
3
Regeneron Pharmaceuticals
REGN
$70.5B
| $21.3M | 6.71% |
61,720
-51,780
| -46% | -$18M |
|
|
4
Sanofi
SNY
$105B
| $20.5M | 6.47% |
511,446
-488,340
| -49% | -$20.3M |
|
5
Viatris
VTRS
$19.8B
| $20.3M | 6.41% |
493,820
-112,680
| -19% | -$4.8M |
|
|
AGN
6
DELISTED
Allergan plc
AGN
| $15.5M | 4.91% |
92,372
+43,472
| +89% | +$7.29M |
|
|
7
Pfizer
PFE
$141B
| $15.5M | 4.88% |
+458,869
| New | +$15.8M |
|
|
8
Cigna
CI
$75.1B
| $15.4M | 4.86% |
+91,800
| New | +$17.8M |
|
|
9
Merck
MRK
$307B
| $15.4M | 4.85% |
+295,976
| New | +$16M |
|
10
Medtronic
MDT
$107B
| $12.8M | 4.05% |
159,850
+22,250
| +16% | +$1.84M |
|
|
ALDR
11
DELISTED
Alder Biopharmaceuticals
ALDR
| $10.5M | 3.3% |
822,890
+36,020
| +5% | +$521K |
|
12
Novartis
NVS
$285B
| $10.3M | 3.25% |
142,067
-86,601
| -38% | -$6.59M |
|
|
13
Amgen
AMGN
$197B
| $10.1M | 3.19% |
+59,300
| New | +$10.9M |
|
14
Ironwood Pharmaceuticals
IRWD
$634M
| $10M | 3.16% |
775,890
-953,977
| -55% | -$11.9M |
|
15
Dr. Reddy's Laboratories
RDY
$10.4B
| $9.65M | 3.04% |
+1,475,660
| New | +$10.3M |
|
|
16
CVS Health
CVS
$137B
| $7.52M | 2.37% |
120,830
-194,670
| -62% | -$14M |
|
|
AET
17
DELISTED
Aetna Inc
AET
| $7.42M | 2.34% |
43,900
-96,300
| -69% | -$17.3M |
|
18
TG Therapeutics
TGTX
$8.26B
| $6.76M | 2.13% |
475,918
-879,260
| -65% | -$11.2M |
|
19
MiMedx Group
MDXG
$645M
| $6.29M | 1.98% |
902,100
+175,800
| +24% | +$2.05M |
|
|
ELGX
20
DELISTED
Endologix Inc
ELGX
| $5.57M | 1.76% |
131,691
-87,932
| -40% | -$3.78M |
|
21
United Therapeutics
UTHR
$22.5B
| $5.28M | 1.67% |
+47,000
| New | +$5.97M |
|
|
NXTM
22
DELISTED
NxStage Medical Inc.
NXTM
| $5.18M | 1.64% |
208,480
-4,720
| -2% | -$115K |
|
23
Bristol-Myers Squibb
BMY
$123B
| $5.16M | 1.63% |
+81,600
| New | +$5.25M |
|
|
SIEN
24
DELISTED
Sientra, Inc.
SIEN
| $5.11M | 1.61% |
52,921
+4,460
| +9% | +$492K |
|
|
ARNA
25
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $5.04M | 1.59% |
+127,564
| New | +$4.96M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q1 2018 Portfolio in Review
As of Q1 2018, Senzar Asset Management held 40 positions worth $317M, down 19% from $392M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Senzar Asset Management withdrew a net $34M in Q1 2018, closing 9 positions and reducing 13 holdings. Its most notable exit was Abbott, an estimated $17.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Financials.
Against the trend, Senzar Asset Management opened a new position in AstraZeneca worth $26.5M.
- Senzar Asset Management's largest Q1 2018 buy was AstraZeneca: 378,855 shares worth $26.5M.
- Senzar Asset Management added most to Allergan plc in Q1 2018, an estimated $7.29M increase.
- Senzar Asset Management's biggest Q1 2018 reduction was Sanofi, cutting an estimated $20.3M.
- Senzar Asset Management fully exited Abbott in Q1 2018, selling an estimated $17.5M.
- Senzar Asset Management's ten largest holdings make up 58% of its $317M portfolio in Q1 2018.
- Senzar Asset Management opened 11 new positions and closed 9 in Q1 2018.
- Senzar Asset Management's portfolio value fell 19% quarter-over-quarter to $317M.
Based on Senzar Asset Management's 13F filing for Q1 2018, filed 14 May 2018.